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Calcimimetics: A new tool for management of hyperparathy-
roidism and renal osteodystrophy in patients with chronic kid-
ney disease. Epidemiologic, clinical, and basic scientific studies
led to an explosion in our understanding of disorders of min-
eral metabolism in the chronic kidney disease (CKD) patient.
These advances are not always translated into improved care
of renal osteodystrophy in CKD-5 patients. The introduction of
a new class of drugs, calcimimetics, allows improved control of
abnormal calcium/phosphorus metabolism. The calcimimetics
compliment, rather than replace, current treatment options for
secondary hyperparathyroidism in the chronic disease patient.
Basic scientific studies have led to an explosion in
our understanding of disorders of mineral metabolism
in chronic renal failure. These advances have been trans-
lated into new therapeutic options that have improved
the care of the patients with stage 5 chronic kidney dis-
ease (CKD). The introduction of a new class of drugs
called calcimimetics has allowed for improved control of
abnormal calcium and phosphorus metabolism. The cal-
cimimetic drugs compliment, rather than replace, current
treatment options for secondary hyperparathyroidism in
the patient with CKD. The understanding of basic sci-
ence and its application to clinical management of sec-
ondary hyperparathyroidism in chronic kidney disease
patients has led to a shift in our thought process in man-
agement of this difficult problem. In recent years, in-
creased emphasis has been placed on controlling serum
phosphorus and normalizing (as opposed to increasing)
serum calcium. Moreover, among practitioners there is
now a greater appreciation of the potential toxicities of
calcium overload with regard to the risk for develop-
ment of vascular calcification. All of these issues form the
basis of the National Kidney Foundation Dialysis Out-
comes Quality Initiative (K/DOQI) guidelines [1, 2]. The
K/DOQI recommendations for optimal management of
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serum calcium, phosphorus, calcium-phosphorus (Ca ×
P) product, and parathyroid hormone (PTH) levels have
often been difficult to attain with the previously available
treatment options, namely, dietary phosphorus restric-
tion, various dietary phosphate binders, and vitamin D
preparations. Unfortunately, the therapeutic options for
secondary hyperparathyroidism that were available over
the last decade have all too often led to vexing clinical
problems, including hypercalcemia, inadequate control
of hyperphosphatemia, increased Ca × P product, and
refractory hyperparathyroidism or oversuppression of
PTH [3]. Paradoxically, efforts to attain the NKF DOQI
goals for management of second hyperparathyroidism
have often exacerbated these abnormalities of mineral
metabolism, making it more difficult to attain the treat-
ment goals for serum calcium and phosphorus and Ca ×
P product.
RESULTS
The cloning of the calcium sensing receptor has led to
the development of new pharmacologic agents that have
added strength and definition to our current armamen-
tarium of therapies for secondary hyperparathyroidism.
These new pharmacologic agents are called calcimimetic
agents. Calcimimetic agents are small organic molecules
that act as allosterse activators of the calcium sensing
receptors (CaSR) in the parathyroid gland and other
tissues. Calcimimetics increase the threshold sensitivity
of the CaSR to extracellular calcium leading to activa-
tion of the CaSR at lower than normal levels of serum
calcium (Fig. 1). As a result, in the presence of these
agents, even the low levels of ionized calcium typically
present in patients with chronic kidney disease exert a
suppressive effect on PTH secretion [5]. Moreover, in
several short-term and long-term studies in experimental
animals with chronic kidney disease, calcimimetics have
been shown to lead to regression of advanced parathyroid
hyperplasia [6, 7] and reversal of osteitis fibrosa cystica [8]
(Fig. 1). Clinical trials of cinacalcet HCl, the first agent
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Fig. 1. Percentage change in PTH and Ca × P levels at 12 weeks
of treatment with cinacalcet HCl (50 or 100 mg/day) or placebo. Re-
produced with permission from Torres PU: Nephrol Dial Transplant
17:723–731, 2002 [5].
in this new class of drugs to be developed and marketed,
are ongoing. In this paper, these clinical trials will be re-
viewed, and the role of calcimimetics used in conjunction
with phosphate binders and vitamin D steroids for attain-
ment K/DOQI treatment goals will be discussed.
Early clinical trials in secondary hyperparathyroidism
The calcimimetic R-568 was the first drug of this class
to be evaluated in patients with stage 5 CKD and sec-
ondary hyperparathyroidism. Two separate R-568 stud-
ies in CKD-5 patients revealed dramatic dose-dependent
decreases in PTH levels within 2 hours of single oral doses
of R-568 [9–11]. When given repeatedly or in single large
doses to humans or experimental animals, calcimimetic
agents not only lower PTH but also decrease calcium lev-
els [9–11]. As PTH levels are lowered, there is a simulta-
neous temporal decline in blood calcium concentrations
[9–11].
In the early single dose study of Amg-073 [12], daily
doses of 50 mg over 8 days were administered to CKD-5
patients, with secondary hyperparathyroidism. PTH val-
ues were reduced by 39% [12]. Importantly, decreases in
serum calcium and phosphorus levels and Ca × P product
were observed even in this early single dose study [12].
These findings became a recurrent theme as the results of
all subsequent international phase II and phase III stud-
ies in both hemodialysis and peritoneal dialysis patients
were reported.
Clinical results from phase II and phase III studies
Data combined from 3 phase II studies conducted
in 142 hemodialysis patients from the United States,
Canada, and Europe, who received cinacalcet HCl doses
of 50 or 100 mg per day for 12 weeks are shown in
Figure 2 [13–15]. Overall, a 25% reduction in PTH levels
was observed in the active treatment group. Furthermore,
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Fig. 2. Vitamin D and calcium affect different components of parathy-
roid gland function. Vitamin D sterols inhibit PTH gene transcrip-
tion and, thus, reduce the amount of hormone that is synthesized and
stored in parathyroid tissues. Vitamin D sterols do not, however, affect
calcium-regulated PTH secretion directly. In contrast, changes in blood,
ionized calcium concentration, modulate PTH release directly by affect-
ing the level of activation of the CaSR. Signaling through the CaSR also
appears to be critically important in the prevention of parathyroid gland
hyperplasia. Reproduced with permission from Goodman WG: Semin
Nephrol 24:17–24, 2004 [21].
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Fig. 3. Calcimimetics increase CaSR sensitivity to extracellular cal-
cium, thus stimulating activation of the CaSR at lower serum calcium
levels than normal.
there was an 8% reduction in Ca × P products. In con-
tract, both Ca × P product and PTH levels increased in
the placebo group.
Lessons learned from phase III placebo
controlled studies
Results from studies of 1100 hemodialysis and peri-
toneal dialysis patients in phase III studies are similar
to those from phase II studies. However, these placebo-
controlled phase III studies were 26 weeks in duration
and cinacalcet HCl doses ranged from 30 to 180 mg per
day. Patients included in these studies had intact PTH
levels (iPTH) >300 pg/mL. The primary end point was
achievement of a mean PTH level ≤200 pg/mL during a
14- to 16-week efficacy assessment period. The results of
these studies are summarized in Figure 3 [16–18].
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Fig. 4. Percentage change in PTH and Ca × P levels at 28 weeks of
treatment with cinacalcet HCl (30-180 mg/day) in 3 phase III placebo-
controlled, double-blind randomized titration studies performed in
North America, Europe, and Australia in hemodialysis and peritoneal
dialysis patients at centers in North America, Europe, and Australia.
Reproduced with permission from Preston Clausen, Amgen, Thousand
Oaks, California.
Extension studies evaluating Amg-073
The patients who were enrolled in either treatment or
placebo groups in phase II studies were evaluated for
another year while receiving cinacalcet HCl at doses as
high as 180 mg [19]. These long-term studies revealed
continued suppression of PTH and reduction of Ca ×
P product for at least 1 year, and as long as 3 years fol-
lowing after open-label initiation of calcimimetic therapy
[5, 19]. Torres et al evaluated femoral neck bone min-
eral density in 6 patients receiving long-term treatment
with cinacalcet HCl [5]. After 3 years of treatment, these
patients experienced an averaged 10% increase in bone
mass at the femoral neck. In contrast, CKD-5 patients
who received conventional treatment for secondary hy-
perparathyroidism experienced a 10% loss of femoral
neck bone density over a 3-year period. These findings
have not yet been confirmed in large-scale clinical tri-
als. Anecdotal observations in the author’s hemodial-
ysis and peritoneal dialysis patient populations suggest
that patients treated with cinacalcet HCl may experience
resolution of calcific arteriopathy with healing of sub-
cutaneous lesions (unpublished observation). Moreover,
patients treated with calcimimetic agents often report im-
provement in joint pain, and complain less of redness of
the eyes.
Side effects and tolerability
Cinacalcet was generally a well-tolerated drug in the
1100 patients enrolled in the international phase III stud-
ies [16–18]. Most reported side effects occurred with sim-
ilar frequency in the cinacalcet and placebo treatment
groups. The only side effects that occurred more fre-
quently in the cinacalcet treatment groups were nausea
and vomiting. In the largest phase III study, which in-
cluded over 400 patients, nausea occurred in 33% of pa-
tients in the cinacalcet HCl treatment group compared
to 19% of patients in the placebo group [17]. However,
throughout these phase III studies, the number of patients
withdrawn from treatment was equivalent in the placebo
and active treatment groups [16–18]. Transient hypocal-
cemia was a frequent occurrence (21% of cinacalcet-
treated patients) during the first 4 weeks of these studies.
It should be noted that all of these studies allowed for
the addition or increase in dose of vitamin D sterols, or
an increase in calcium-containing phosphate binders for
treatment of hypocalcemia.
Phosphate binders and vitamin D therapy in phase II and
III studies
In the phase II and III studies, the average doses of
phosphate binding agents and vitamin D sterols did not
differ between placebo and treatment groups [14–18]. It
is also important to note that treatment with cinacal-
cet HCl resulted in a decrease in PTH levels regard-
less of increases, decreases, or no change in vitamin D
sterol doses. In the author’s experience, treatment with
cinacalcet HCl often allows for successful treatment with
vitamin D sterols in patients who previously had not tol-
erated these compounds due to increases in serum phos-
phorus levels or Ca × P product. In the study by Block
et al, vitamin D sterols had been previously been with-
held from 20% of the patients participating in this phase
III study due to increased serum calcium or phosphorus,
or both [17]. However, during treatment with cinacalcet
HCl, these patients experience a reduction in serum cal-
cium and phosphorus levels and Ca × P product such that
they were then able to tolerate treatment with vitamin D
sterols.
CONCLUSION
In cinacalcet HCl-treated patients, reductions in
parathyroid hormone levels are accompanied by signifi-
cant reductions in serum calcium, serum phosphorus, and
Ca × P product. Based on available studies, cinacalcet
HCl promises to be a very valuable addition to our ar-
mamentarium for treatment of secondary hyperparathy-
roidism in patients with stage 5 chronic kidney disease on
maintenance hemodialysis or peritoneal dialysis. Treat-
ment with cinacalcet HCl appears to result in substantial
reduction in PTH levels without leading to hypercal-
cemia, hyperphosphatemia, or increased Ca × P product.
Improvement in these parameters of mineral metabolism
could theoretically lead to a reduction in risk of car-
diovascular calcification in dialysis patients. Moreover,
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addition of cinacalcet HCl to a treatment regimen consist-
ing of dietary phosphorus restriction, phosphate binders,
and vitamin D sterols may increase the likelihood of
achieving the stringent goals for calcium, phosphorous,
Ca × P product, and PTH recommended in the K/DOQI
guidelines.
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